ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.

Derrick M Oaxaca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.